NCT02171351

Brief Summary

Physical activity (PA) is recommended for the treatment of subjects with type 2 diabetes to increase insulin sensitivity and improve metabolic control. However, adherence to PA is often poor, due to a lack of motivation or due to disabling complications or comorbidities. Neuromuscular electrostimulation (NMES) is a physical treatment commonly used to improve muscle strength and volume in several situations: after stroke, after limb trauma or during chest rehabilitation in deconditioned patients. The investigators have already shown in a first pilot study (manuscript in preparation) that NMES improves insulin sensitivity : in the study ELECTRODIAB (No. ID-RCB: 2011-A00930-41), the investigators showed a 25% insulin sensitivity improvement after a week of daily 25-min bi-quadricipital NMES session, in a population of patients with orally-treated type 2 diabetes. Insulin sensitivity increased up to 50% in the most deconditioned subjects. Discrepancy between this result and the very low energy expenditure measured during sessions suggests that the metabolic effect was not solely mediated by muscle contractions. The investigators hypothesize the involvement of neurological pathways. Indeed, it is demonstrated that the autonomic nervous system is an important regulator of glucose metabolism with pancreatic action, a key role in energy metabolism and a complex relationship with insulin resistance. Muscle activity, whether static (isometric) or dynamic causes changes in sympathetic nerve activity in healthy subjects but its effect in type 2 diabetic subjects is not known. The investigators hypothesize that, in type 2 diabetic subjects, the modulation of sympathetic nerve activity by NMES could be involved in the improvement of insulin sensitivity. To address this question, the investigators propose to assess sympathetic nerve activity with the gold standard method of microneurography before and after a single bi-quadricipital NMES session. The impact of neuro-electro-stimulation (NES) (a sensitive stimulation under muscular threshold) and the impact of voluntary isometric muscle contractions (VC) will also be evaluated. These procedures will also be applied in healthy control subjects.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2020

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 24, 2014

Completed
6.1 years until next milestone

Study Start

First participant enrolled

August 1, 2020

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
Last Updated

August 24, 2022

Status Verified

August 1, 2020

Enrollment Period

1.3 years

First QC Date

June 18, 2014

Last Update Submit

August 23, 2022

Conditions

Keywords

sympathetic nerve reactivityneuromuscular electrostimulation

Outcome Measures

Primary Outcomes (1)

  • Sympathetic nerve reactivity in response to a single session of neuromuscular electrostimulation

    Sympathetic nerve reactivity will be assessed by plethysmography, with a Valsalva procedure, at baseline and every 5 minutes during a 20-min session of biquadricipital neuromuscular electrostimulation

    at 0, 5, 10, 15, 20 min of the NMES session

Secondary Outcomes (2)

  • sympathetic nerve reactivity in response to a single session of neuro electrostimulation

    at 0, 5, 10, 15, 20 min of the NES session

  • sympathetic nerve reactivity in response to a single session of voluntary muscular contractions

    at 0, 5, 10, 15, 20 min of the VC session

Other Outcomes (1)

  • comparison of sympathetic nerve reactivity between the different groups and procedures

    at 0, 5, 10, 15, 20 min of each session

Study Arms (3)

effect of neuromuscular electrostimulation (NMES)

EXPERIMENTAL
Device: effect of neuromuscular electrostimulation (NMES)

effect of neuro electrostimulation (NES)

EXPERIMENTAL
Device: effect of neuro electrostimulation (NES)

effect of voluntary contractions (VC)

EXPERIMENTAL
Other: effect of voluntary contractions (VC)

Interventions

Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuromuscular electrostimulation (NMES).

effect of neuromuscular electrostimulation (NMES)

Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuro electrostimulation (NES)

effect of neuro electrostimulation (NES)

Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of voluntary contractions (VC)

effect of voluntary contractions (VC)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • type 2 diabetes for at least 12 month
  • treatment by oral hypoglycemic agents and/or GLP1 agonists
  • HbA1c : 6-10%
  • suspected insulin-resistance (at least one criteria below) :
  • waist circumference \> 80cm (female); \> 94cm (male)
  • triglycerides \> 150 mg/dl
  • HDL-cholesterol \< 50 mg/dl (female); \< 40 mg/dl (male)
  • low background physical activity (Ricci-Gagnon score \< 27)

You may not qualify if:

  • type 1 diabetes
  • treatment with insulin
  • seizure
  • pace maker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Research Center Caen University Hospital

Caen, 14033, France

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Insulin Resistance

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesHyperinsulinism

Study Officials

  • Michael Joubert, MD

    University Hospital, Caen

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2014

First Posted

June 24, 2014

Study Start

August 1, 2020

Primary Completion

December 1, 2021

Study Completion

June 1, 2022

Last Updated

August 24, 2022

Record last verified: 2020-08

Locations